ArticleJAMA oncology2020
Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma.
Article in JAMA oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Label-Free Raman Spectroscopy Reveals Metabolic Signatures Associated with MGMT Promoter Methylation Status in Glioblastoma.Analytical chemistry · 2026Article
- Accessibility to molecular studies in gliomas: a challenge for precision medicine in low-resource countries.Frontiers in oncology · 2026Article
- Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes.Journal of neuro-oncology · 2025Article
- Enhancing neuro-oncology care through equity-driven applications of artificial intelligence.Neuro-oncology · 2024Review
- Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.Journal of neuropathology and experimental neurology · 2024Article
- Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment.NPJ precision oncology · 2024Review
- MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Advanced molecular diagnostic tools: A step closer to precision medicine in neuro-oncology.Neuro-oncology · 2023Article
- An evaluation of biobanking and therapeutic clinical trial representation among adult glioma patients from rural and urban Utah.Neuro-oncology practice · 2023Article
- Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2023Article
- National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.Neuro-oncology · 2023Article
- The predictive value of partialNeuro-oncology practice · 2023Article
- Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States.Neuro-oncology practice · 2023Article
- METTL3 knockdown promotes temozolomide sensitivity of glioma stem cells via decreasing MGMT and APNG mRNA stability.Cell death discovery · 2023Article
- Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.Neuro-oncology · 2022Article
- Assessment of radiographic and prognostic characteristics of programmed death-ligand 1 expression in high-grade gliomas.Journal of neuro-oncology · 2022Article
- Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.Neuro-oncology · 2022Article
- Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.Journal of neuro-oncology · 2022Article
- Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects.Signal transduction and targeted therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.